Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression-Reference-Cited by-同舟云学术

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

Published:2016-01 Issue:1 Volume:29 Page:75-89
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Hayes Tikvah K.,Neel Nicole F.,Hu Chaoxin,Gautam Prson,Chenard Melissa,Long Brian,Aziz Meraj,Kassner Michelle,Bryant Kirsten L.,Pierobon Mariaelena,Marayati Raoud,Kher Swapnil,George Samuel D.,Xu Mai,Wang-Gillam Andrea,Samatar Ahmed A.,Maitra Anirban,Wennerberg Krister,Petricoin Emanuel F.,Yin Hongwei H.,Nelkin Barry,Cox Adrienne D.,Yeh Jen Jen,Der Channing J.

Funder

NIH

Lustgarten Pancreatic Cancer Foundation

Pancreatic Cancer Action Network

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference44 articles.

1. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer;Alagesan;Clin. Cancer Res.,2015

2. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse;Bardeesy;Proc. Natl. Acad. Sci. USA,2006